MitoSense, Inc.
MitoSense, Inc. is a research and development company focused on developing treatments for neurodegenerative diseases through innovative mitochondrial therapies. With exclusive licensing of Mitochondria Organelle Transplantation (MOT™) technology, MitoSense aims to improve the lives of patients suffering from conditions such as ALS, Alzheimer's, and Parkinson's disease.
What We Do
Mitochondria Organelle Transplantation (MOT™)
A proprietary technique to replenish mitochondria in humans, aimed at treating neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's.
Biologics
Digital Health Technologies
Key People
News & Updates
MitoSense Inc. announces the publication of a study on alternative mitochondrial donors.
MitoSense supports a benefit concert aimed at raising awareness for ALS and TBI.
MitoSense announces its participation in the Military Health System Research Symposium.
MitoSense has been accepted into the NVIDIA Inception Program, marking a significant milestone for the company.